GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » ROE % Adjusted to Book Value

RNAZ (TransCode Therapeutics) ROE % Adjusted to Book Value : -104.76% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is TransCode Therapeutics ROE % Adjusted to Book Value?

TransCode Therapeutics's ROE % for the quarter that ended in Sep. 2024 was -624.34%. TransCode Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was 5.96. TransCode Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -104.76%.

TransCode Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for TransCode Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransCode Therapeutics ROE % Adjusted to Book Value Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - - - -301.50

TransCode Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -540.93 -213.42 -491.46 -127.38 -104.76

Competitive Comparison of TransCode Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, TransCode Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TransCode Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where TransCode Therapeutics's ROE % Adjusted to Book Value falls into.


;
;

TransCode Therapeutics ROE % Adjusted to Book Value Calculation

TransCode Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-759.77% / 2.52
=-301.50%

TransCode Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-624.34% / 5.96
=-104.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of TransCode Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

TransCode Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TransCode Therapeutics Inc (NAS:RNAZ) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
KRBPQ RMTG CYTOF AIBT GSTC CNBX HEPA GBLX ENDV PPCB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
6 Liberty Square, Suite 2382, Boston, MA, USA, 02109
Website
https://www.transcodetherapeutics.com
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
Executives
Robert Michael Dudley director, 10 percent owner, officer: Chief Executive Officer C/O TRANSCODE THERAPEUTICS, 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Thomas A Fitzgerald director, officer: VP, Chief Financial Officer C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Anna Moore 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE #2382, BOSTON MA 02109
Zdravka Medarova 10 percent owner C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109
Erik Manting director C/O TRANSCODE THERAPEUTICS, INC., 6 LIBERTY SQUARE, #2382, BOSTON MA 02109